TEL AVIV, Israel and BETHESDA, Maryland, September 21, 2021 / PRNewswire / – Cannabic Pharmaceuticals Inc. (CNBX), a global leader in the development of cannabinoid drugs linked to cancer, today announced the hiring of Dr. David Sans FAARM, PhD, MBA in new York to expand its current portfolio of clinical development assets in the field of mental illnesses. This announcement follows the company’s commitment to expand current drug development programs with a second generation of synthetic drugs inspired by psychedelics.
Gabriel Yariv, executive chairman of the company said, âPsychedelic compounds benefit from an increasingly favorable regulatory environment and a growing body of clinical trial data demonstrating remarkable efficacy in difficult mental health disorders. treat. It is for these reasons that we are interested in this area, to help patients who are struggling to treat their mental illnesses and to have a positive impact by expanding our current pipeline of synthetic compounds and investing in a second generation synthetic psychedelic medicine. well positioned. “
Eyal barad, the co-founder and CEO of Cannabics Pharmaceuticals commented: âDr. David Sans is a healthcare investment banker in new York with over 12 years of banking experience and a wealth of knowledge in the CNS industry. David has led a number of very relevant transactions for Cannabics Pharmaceuticals and we look forward to the opportunity to work with him. “
About Cannabics Pharmaceuticals:
Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) is a US public company and a world leader in the development of cannabinoid drugs related to cancer. The Company’s R&D is based in Israel, where he is authorized by the Department of Health to conduct scientific and clinical research on cannabinoid formulations and cancer. For more information, please visit www.cannabics.com. For the latest updates on Cannabics Pharmaceuticals, follow the Company on Twitter @Cannabics, Facebook @CannabicsPharmaceuticals, LinkedIn and on Instagram @Cannabics_Pharmaceuticals.
Recent expansion of the Cannabics Pharmaceuticals Advisory Board to include: Teacher. Caroline robert (MD, Ph.D.), melanoma specialist, and, Dr. Sigal Tavor (MD), expert in hematology, with Prof. Amos Toren (MD), Prof. Zamir Halpern (MD), Prof. Noam Shomron (Ph.D.), Dr. Erez Scapa (MD), Dr. Dana Ben-Ami Shor (MD), Dr. Sigalit Arieli-Portnoy (Ph.D.) and Dr. Tal Mofkadi (Ph.D.).
Recent expansion of the Cannabics Pharmaceuticals Board of Directors to include: Dr Inbar Maymon-Pomeranchik (Ph.D.), and Dr. Gil Feiler (Doctorate.) as independent directors.
Certain statements contained in this press release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other US federal securities laws. Such statements include, but are not limited to, statements identified by words such as “believes”, “expects”, “anticipates”, “believes”, “intention”, “plans”, ” objectives â,â projects âand similar expressions. The statements contained in this press release are based on the current beliefs and expectations of the management of our company and are subject to significant risks and uncertainties. Actual results may differ from those described in forward-looking statements. There are many factors that could cause or contribute to such differences, including, but not limited to the results of clinical trials and other studies, the challenges inherent in new product development initiatives, the effect of any competitive product, our ability to license and protect our intellectual property. , our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and regulations, potential litigation by or against us, any government review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our last filed 10-Q report July 14, 2021. We assume no obligation to update any forward-looking statements or information contained in this press release or other public disclosures at any time. Finally, the investing public is reminded that the only announcements or information concerning Cannabics Pharmaceuticals Inc., which are tolerated by the Company, must come from the Company itself and bear our name as the source.
For more information on cannabis:
Cannabics Pharmaceuticals Inc.
Telephone: +1 (877) 424-2429
SOURCE Cannabics Pharmaceuticals Inc.